120 results
Page 2 of 6
6-K
EX-99.1
id8p3
28 Jun 22
ObsEva Announces UK MHRA Marketing Authorization for Yselty® (linzagolix), an Oral GnRH Antagonist, for the Treatment of Uterine Fibroids
4:13pm
6-K
EX-99.1
x9sesflrcr2cc0hzaf
17 Jun 22
ObsEva Announces European Commission Marketing Authorization for Yselty® (linzagolix), an Oral GnRH Antagonist, for the Treatment of Uterine Fibroids
7:05am
6-K
EX-99.1
zjf7xh5rz
27 May 22
ObsEva Announces Corporate Updates
4:56pm
6-K
ijh00vz
27 May 22
ObsEva Announces Corporate Updates
4:56pm
6-K
7g1wqc
17 May 22
Index to Unaudited Condensed Consolidated Financial Statements
7:00am
6-K
EX-99.3
6to fphp7hz
17 May 22
Index to Unaudited Condensed Consolidated Financial Statements
7:00am
6-K
EX-99.1
jgl4n
2 May 22
ObsEva Announces Appointment of Dr. Brandi Howard as Chief Clinical Officer
7:00am
6-K
EX-99.1
u09zk6q21t
25 Apr 22
ObsEva Announces Confirmation of Positive CHMP Opinion for Linzagolix, an Oral GnRH
7:00am
6-K
EX-99.1
ijf7y6n03hy
22 Mar 22
Current report (foreign)
7:28am
6-K
EX-99.1
5lst 4qoj
10 Mar 22
ObsEva Announces Year End 2021 Financial Results and Provides Corporate Update
7:11am
6-K
EX-99.1
nje3of
10 Feb 22
ObsEva Enters into Licensing Agreement with Theramex for the Commercialization of Linzagolix
4:27pm
6-K
EX-99.1
oj6h9o044xidwteu0
4 Feb 22
ObsEva Provides Update on EU Marketing Authorisation Process for Linzagolix, an Oral
4:37pm
6-K
EX-99.1
ssl9kcg
1 Feb 22
ObsEva Appoints Katja Buhrer as Chief Strategy Officer
6:05am
6-K
dd0eog3wssobi
28 Jan 22
ObsEva Announces Corporate Updates
5:16pm
6-K
EX-99.1
tg9yo1fm h1hi21
28 Jan 22
ObsEva Announces Corporate Updates
5:16pm
6-K
EX-99.3
nlbg7814ya4 8a
28 Jan 22
ObsEva Announces Corporate Updates
5:16pm